Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6164-6174

  Walsh, Alex J ^a   Cook, Rebecca S ^b,d   Manning, H Charles ^a,c   Hicks, Donna J ^b   Lafontant, Alec ^a   Arteaga, Carlos L ^b,d   Skala, Melissa C ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b Institute of Imaging Science   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CASPASE 3; CYANIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLAVINE ADENINE NUCLEOTIDE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IMMUNOGLOBULIN G; KI 67 ANTIGEN; LACTIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL HETEROGENEITY; CELL METABOLISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LACTATION; METABOLIC INHIBITION; MITOSIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; OPTICAL METABOLIC IMAGING; OXIDATIVE PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLAVIN-ADENINE DINUCLEOTIDE; GLYCOLYSIS; HUMANS; MICE; MICE, NUDE; NAD; OPTICAL IMAGING; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886082158     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0527     Document Type: Article

References (50)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
2. Plas DR, Thompson CB Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24: 7435-42.
3. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19:6102-14.
4. Ross JS, Fletcher JA The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16:413-28.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil J.C., Harris LN, Fehrenbacher L, et al Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
6. Yakes FM, Chinratanalab W, Ritter C.A., King W., Seelig S, Arteaga CL Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62:4132-41.
7. Shah C, Miller TW, Wyatt S.K., McKinley ET, Olivares MG, Sanchez V, et al Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009; 15:4712-21.
8. Walsh A, Cook RS, Rexer B, Arteaga C.L., Skala MC Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomed Opt Express 2012; 3:75-85.
9. Brown RS, Wahl RL Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72:2979-85.
10. Wang L, Zhang Q, Zhang J., Sun S, Guo H, Jia Z., et al PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011; 11:248.
11. Zhang D, Tai LK, Wong L.L., Chiu LL, Sethi SK, Koay ES Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 2005; 4:1686-96.
12. Nguyen QD, Perumal M, Waldman T.A., Aboagye EO Glucose metabolism measured by [F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol 2011; 4:241-8.
13. Specht JM, Kurland BF, Montgomery S.K., Dunnwald LK, Doot RK, Gralow JR, et al Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010; 16:2803-10.
14. Basu S, Chen W, Tchou J., Mavi A, Cermik T, Czerniecki B., et al Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008; 112:995-1000.
15. Jacobs MA, Ouwerkerk R, Wolff A.C., Gabrielson E., Warzecha H, Jeter S, et al Monitoring of neoadjuvant chemotherapy using multiparametric, (23)Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat 2011; 128: 119-26.
16. Mankoff DA, Dunnwald LD LK, Doot RK, Specht JM, Gralow JR, Ellis G.K., et al PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 2011; 17:2400-9.
17. Minami H, Kawada K, Murakami K., Sato T, Kojima Y, Ebi H., et al Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 2007; 37:44-8.
18. Reilly RM, McLarty K, Fasih A., Scollard DA, Done SJ, Vines DC, et al (18)F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med 2009; 50:1848-56.
19. Chance B, Schoener B, Oshino R., Itshak F, Nakase Y. Oxidationreduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J Biol Chem 1979; 254: 4764-71.
20. Skala MC, Riching KM, Gendron-Fitzpatrick A, Eickhoff J., Eliceiri KW, White JG, et al In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia. Proc Natl Acad Sci U S A 2007; 104:19494-9.
21. Walsh AJ, Poole KM, Duvall C.L., Skala MC Ex vivo optical metabolic measurements from cultured tissue reflect in vivo tissue status. J Biomed Opt 2012; 17:116015.
22. Lakowicz J. Principles of fluorescence spectroscopy. New York: Plenum Publishers; 1999.
23. Lakowicz JR, Szmacinski H, Nowaczyk K., Johnson ML Fluorescence lifetime imaging of free and protein-bound Nadh. Proc Natl Acad Sci U S A 1992; 89:1271-5.
24. Nakashima N, Yoshihara K, Tanaka F., Yagi K. Picosecond fluorescence lifetime of the coenzyme of D-amino acid oxidase. J Biol Chem 1980; 255:5261-3.
25. Maeda-Yorita K., Aki K. Effect of nicotinamide adenine dinucleotide on the oxidation-reduction potentials of lipoamide dehydrogenase from pig heart. J Biochem 1984; 96:683-90.
26. Sidani M, Wyckoff J, Xue C.S., Segall JE, Condeelis J. Probing the microenvironment of mammary tumors using multiphoton microscopy. J Mammary Gland Biol 2006; 11:151-63.
27. Bird DK, Yan L, Vrotsos K.M., Eliceiri KW, Vaughan EM, Keely PJ, et al Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res 2005; 65:8766-73.
28. Ritter CA, Perez-Torres M, Rinehart C., Guix M, Dugger T, Engelman J.A., et al Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13:4909-19.
29. Miller TW, Forbes JT, Shah C, Wyatt S.K., Manning HC, Olivares MG, et al Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009; 15:7266-76.
30. Gee MS, Upadhyay R, Bergquist H., Alencar H, Reynolds F, Maricevich M., et al Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 2008; 248:925-35.
31. Dandekar M, Tseng JR, Gambhir SS Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007; 48: 602-7.
32. Fueger BJ, Czernin J, Hildebrandt I., Tran C, Halpern BS, Stout D, et al Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 2006; 47:999-1006.
33. McKinley ET, Bugaj JE, Zhao P, Guleryuz S., Mantis C, Gokhale PC, et al 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 2011; 17:3332-40.
34. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974; 19:716-23.
35. Huang S, Heikal AA, Webb WW Two-photon fluorescence spectroscopy and microscopy of NAD(P)H and flavoprotein. Biophys J 2002; 82:2811-25.
36. Yu Q, Heikal AA Two-photon autofluorescence dynamics imaging reveals sensitivity of intracellular NADH concentration and conformation to cell physiology at the single-cell level. J Photochem Photobiol B 2009; 95:46-57.
37. Cheng CM, Cohen M, Wang J., Bondy CA Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. FASEB J 2001; 15:907-15.
38. Ostrander JH, McMahon CM, Lem S, Millon S.R., Brown JQ, Seewaldt VL, et al Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status. Cancer Res 2010; 70:4759-66.
39. Chen JQ, Brown TR, Russo J. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta 2009; 1793:1128-43.
40. Yadav RN. Isocitrate dehydrogenase activity and its regulation by estradiol in tissues of rats of various ages. Cell Biochem Funct 1988; 6:197-202.
41. Pastorelli R, Carpi D, Airoldi L., Chiabrando C, Bagnati R, Fanelli R., et al Proteome analysis for the identification of in vivo estrogen-regulated proteins in bone. Proteomics 2005; 5:4936-45.
42. Narayan M, Wilken JA, Harris L.N., Baron AT, Kimbler KD, Maihle NJ Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009; 69:2191-4.
43. Kuznetsov AV, Usson Y, Leverve X., Margreiter R. Subcellular heterogeneity of mitochondrial function and dysfunction: evidence obtained by confocal imaging. Mol Cell Biochem 2004; 256-257:359-65.
44. Benard F, Aliaga A, Rousseau J.A., Cadorette J., Croteau E, van Lier JE, et al A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2[F-18]fluoro-D- glucose in murine models of breast cancer. Mol Imaging Biol 2007; 9:144-50.
45. Drezek R, Brookner C, Pavlova I., Boiko I, Malpica A, Lotan R., et al Autofluorescence microscopy of fresh cervical-tissue sections reveals alterations in tissue biochemistry with dysplasia. Photochem Photobiol 2001; 73:636-41.
46. Skala MC, Fontanella A, Lan L., Izatt JA, Dewhirst MW Longitudinal optical imaging of tumor metabolism and hemodynamics. J Biomed Opt 2010; 15:011112.
47. Suhling K, French PM, Phillips D. Time-resolved fluorescence microscopy. Photochem Photobiol Sci 2005; 4:13-22.
48. Kamohara S, Burcelin R, Halaas J.L., Friedman JM, Charron MJ Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997; 389:374-7.
49. Hundal RS, Petersen KF, Mayerson A.B., Randhawa PS, Inzucchi S, Shoelson SE, et al Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109:1321-6.
50. Kantor PF, Lucien A, Kozak R., Lopaschuk GD The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3ketoacyl coenzyme A thiolase. Circ Res 2000; 86:580-8.